Ambee Pharmaceuticals Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 4/6
Ambee Pharmaceuticals has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 15.7% per year. Ambee Pharmaceuticals's return on equity is 46.5%, and it has net margins of 5%.
Key information
8.3%
Earnings growth rate
8.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | -15.7% |
| Return on equity | 46.5% |
| Net Margin | 5.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ambee Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 209 | 11 | 99 | 0 |
| 30 Sep 23 | 208 | 10 | 98 | 0 |
| 30 Jun 23 | 198 | 9 | 92 | 0 |
| 31 Mar 23 | 191 | 9 | 87 | 0 |
| 31 Dec 22 | 180 | 9 | 82 | 0 |
| 30 Sep 22 | 186 | 8 | 85 | 0 |
| 30 Jun 22 | 181 | 8 | 83 | 0 |
| 31 Mar 22 | 134 | -13 | 64 | 0 |
| 31 Dec 21 | 136 | -13 | 65 | 0 |
| 30 Sep 21 | 109 | -13 | 52 | 0 |
| 30 Jun 21 | 99 | -13 | 48 | 0 |
| 31 Mar 21 | 147 | -1 | 74 | 0 |
| 31 Dec 20 | 188 | 1 | 96 | 0 |
| 30 Sep 20 | 241 | 2 | 118 | 0 |
| 30 Jun 20 | 285 | 4 | 140 | 0 |
| 31 Mar 20 | 311 | 3 | 145 | 0 |
| 31 Dec 19 | 316 | 3 | 147 | 0 |
| 30 Sep 19 | 313 | 3 | 146 | 0 |
| 30 Jun 19 | 321 | 3 | 149 | 0 |
| 31 Mar 19 | 336 | 8 | 161 | 0 |
| 31 Dec 18 | 344 | 9 | 166 | 0 |
| 30 Sep 18 | 347 | 8 | 167 | 0 |
| 30 Jun 18 | 349 | 8 | 166 | 0 |
| 31 Mar 18 | 350 | 8 | 161 | 0 |
| 31 Dec 17 | 352 | 8 | 159 | 0 |
| 30 Sep 17 | 355 | 8 | 160 | 0 |
| 30 Jun 17 | 352 | 7 | 159 | 0 |
| 31 Mar 17 | 352 | 5 | 168 | 0 |
| 31 Dec 16 | 337 | 4 | 160 | 0 |
| 30 Sep 16 | 340 | 3 | 160 | 0 |
| 30 Jun 16 | 341 | 5 | 160 | 0 |
| 30 Sep 15 | 348 | 7 | 154 | 0 |
| 30 Jun 15 | 366 | 8 | 167 | 0 |
| 31 Mar 15 | 349 | 7 | 158 | 0 |
| 31 Dec 14 | 344 | 8 | 156 | 0 |
Quality Earnings: AMBEEPHA has a high level of non-cash earnings.
Growing Profit Margin: AMBEEPHA's current net profit margins (5%) are higher than last year (4.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMBEEPHA's earnings have grown by 8.3% per year over the past 5 years.
Accelerating Growth: AMBEEPHA's earnings growth over the past year (20.9%) exceeds its 5-year average (8.3% per year).
Earnings vs Industry: AMBEEPHA earnings growth over the past year (20.9%) exceeded the Pharmaceuticals industry -2.6%.
Return on Equity
High ROE: Whilst AMBEEPHA's Return on Equity (46.5%) is outstanding, this metric is skewed due to their high level of debt.